Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML.

Cancer Cell. 2008 Oct 7;14(4):335-43. doi: 10.1016/j.ccr.2008.08.014.

2.

Going with the flow: JAK-STAT signaling in JMML.

Kalaitzidis D, Gilliland DG.

Cancer Cell. 2008 Oct 7;14(4):279-80. doi: 10.1016/j.ccr.2008.09.006.

3.

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM.

Haematologica. 2016 Oct;101(10):1190-1199. Epub 2016 Jul 14.

4.

Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement.

Gaipa G, Bugarin C, Longoni D, Cesana S, Molteni C, Faini A, Timeus F, Zecca M, Biondi A.

Leukemia. 2009 Apr;23(4):791-3. doi: 10.1038/leu.2008.265. Epub 2008 Oct 2. No abstract available.

PMID:
18830265
5.

Aberrant phosphorylation of STAT5 by granulocyte-macrophage colony-stimulating factor in infant cytomegalovirus infection mimicking juvenile myelomonocytic leukemia.

Nishio N, Takahashi Y, Tanaka M, Xu Y, Yoshida N, Sakaguchi H, Doisaki S, Hama A, Muramatsu H, Shimada A, Kojima S.

Leuk Res. 2011 Sep;35(9):1261-4. doi: 10.1016/j.leukres.2011.04.014. Epub 2011 May 14.

PMID:
21571368
6.

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.

Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L, Sullivan SK, Tasian SK, Weng J, Favre H, Choi JK, French DL, Loh ML, Weiss MJ.

Blood. 2013 Jun 13;121(24):4925-9. doi: 10.1182/blood-2013-01-478412. Epub 2013 Apr 25.

7.

CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.

Javadi M, Richmond TD, Huang K, Barber DL.

J Biol Chem. 2013 Jul 5;288(27):19459-70. doi: 10.1074/jbc.M113.475087. Epub 2013 May 21.

8.

SOCS2: inhibitor of JAK2V617F-mediated signal transduction.

Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Röhrs S, Romani J, Scherr M, Zaborski M, Drexler HG.

Leukemia. 2008 Dec;22(12):2169-75. doi: 10.1038/leu.2008.226. Epub 2008 Sep 4.

PMID:
18769447
9.

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG.

Blood. 2009 Apr 30;113(18):4414-24. doi: 10.1182/blood-2008-10-182626. Epub 2009 Jan 29.

10.

Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.

Timeus F, Crescenzio N, Baldassarre G, Doria A, Vallero S, Foglia L, Pagliano S, Rossi C, Silengo MC, Ramenghi U, Fagioli F, Cordero di Montezemolo L, Ferrero GB.

Oncol Rep. 2013 Aug;30(2):553-9. doi: 10.3892/or.2013.2535. Epub 2013 Jun 11.

11.

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.

Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A.

Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7.

12.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

13.

Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.

Medves S, Noël LA, Montano-Almendras CP, Albu RI, Schoemans H, Constantinescu SN, Demoulin JB.

Haematologica. 2011 Oct;96(10):1406-14. doi: 10.3324/haematol.2011.040147. Epub 2011 Jun 17.

14.

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.

Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, Irwin MS, Loh ML, Ohh M.

Cancer Res. 2013 Apr 15;73(8):2540-50. doi: 10.1158/0008-5472.CAN-12-3425. Epub 2013 Feb 11.

15.

Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease.

Xiao W, Ando T, Wang HY, Kawakami Y, Kawakami T.

Blood. 2010 Dec 23;116(26):6003-13. doi: 10.1182/blood-2010-05-283937. Epub 2010 Sep 21.

16.

Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.

Tanaka M, Takahashi Y, Xu Y, Yoshida N, Yoshimi A, Villalobos IB, Hama A, Nishio N, Hidaka H, Wang Y, Yagasaki H, Kojima S.

Leuk Res. 2008 Jul;32(7):1036-42. doi: 10.1016/j.leukres.2007.11.016. Epub 2008 Mar 4.

PMID:
18164384
17.

Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.

Gao SM, Chen CQ, Wang LY, Hong LL, Wu JB, Dong PH, Yu FJ.

Exp Hematol. 2013 Mar;41(3):261-70.e4. doi: 10.1016/j.exphem.2012.10.012. Epub 2012 Oct 27.

PMID:
23111066
18.

Single-cell, phosphoepitope-specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection.

Lee AW, Sharp ER, O'Mahony A, Rosenberg MG, Israelski DM, Nolan GP, Nixon DF.

J Virol. 2008 Apr;82(7):3702-12. doi: 10.1128/JVI.01582-07. Epub 2008 Jan 23.

19.

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, Dobrzanski P.

Blood. 2008 Jun 15;111(12):5663-71. Epub 2007 Nov 5.

20.

Juvenile myelomonocytic leukemia.

Proytcheva M.

Semin Diagn Pathol. 2011 Nov;28(4):298-303. Review.

PMID:
22195407

Supplemental Content

Support Center